Robbie Marcus
Stock Analyst at JP Morgan
(3.86)
# 651
Out of 4,915 analysts
162
Total ratings
55.05%
Success rate
7.94%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EW Edwards Lifesciences | Maintains: Neutral | $80 → $85 | $79.31 | +7.17% | 5 | Jul 25, 2025 | |
| COO The Cooper Companies | Downgrades: Neutral | $110 → $76 | $70.69 | +7.51% | 5 | May 30, 2025 | |
| NPCE NeuroPace | Maintains: Overweight | $14 → $16 | $8.51 | +88.01% | 5 | May 14, 2025 | |
| CVRX CVRx, Inc. | Downgrades: Underweight | $15 → $7 | $7.96 | -12.06% | 6 | May 9, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Overweight | $128 → $105 | $91.65 | +14.57% | 6 | May 6, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $12 | $13.14 | -8.68% | 6 | May 6, 2025 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $235 → $195 | $124.54 | +56.58% | 5 | May 6, 2025 | |
| CNMD CONMED | Maintains: Neutral | $70 → $58 | $51.15 | +13.39% | 7 | May 1, 2025 | |
| RXST RxSight | Downgrades: Underweight | $40 → $17 | $7.78 | +118.51% | 5 | Apr 4, 2025 | |
| MMSI Merit Medical Systems | Initiates: Overweight | $120 | $84.86 | +41.41% | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $36 | $21.76 | +65.44% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $392.73 | +13.31% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $481.09 | +40.31% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $6.52 | +99.39% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $110 | $104.92 | +4.84% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $330 | $288.40 | +14.42% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $14.40 | +122.22% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $35.10 | +13.96% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $85 | $80.77 | +5.24% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $71.32 | +26.19% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $26.80 | +86.57% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $5.38 | +48.84% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $252.27 | -0.90% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $16 | $18.79 | -14.85% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $6.30 | +11.11% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $13.63 | +24.72% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $126.19 | -6.49% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $140.18 | +11.29% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $90.24 | +16.36% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $86.09 | -53.54% | 2 | May 5, 2020 |
Edwards Lifesciences
Jul 25, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $79.31
Upside: +7.17%
The Cooper Companies
May 30, 2025
Downgrades: Neutral
Price Target: $110 → $76
Current: $70.69
Upside: +7.51%
NeuroPace
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $8.51
Upside: +88.01%
CVRx, Inc.
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $7.96
Upside: -12.06%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Overweight
Price Target: $128 → $105
Current: $91.65
Upside: +14.57%
Integra LifeSciences Holdings
May 6, 2025
Maintains: Underweight
Price Target: $24 → $12
Current: $13.14
Upside: -8.68%
Inspire Medical Systems
May 6, 2025
Maintains: Overweight
Price Target: $235 → $195
Current: $124.54
Upside: +56.58%
CONMED
May 1, 2025
Maintains: Neutral
Price Target: $70 → $58
Current: $51.15
Upside: +13.39%
RxSight
Apr 4, 2025
Downgrades: Underweight
Price Target: $40 → $17
Current: $7.78
Upside: +118.51%
Merit Medical Systems
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $84.86
Upside: +41.41%
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $21.76
Upside: +65.44%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $392.73
Upside: +13.31%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $481.09
Upside: +40.31%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $6.52
Upside: +99.39%
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $104.92
Upside: +4.84%
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $288.40
Upside: +14.42%
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $14.40
Upside: +122.22%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $35.10
Upside: +13.96%
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $80.77
Upside: +5.24%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $71.32
Upside: +26.19%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $26.80
Upside: +86.57%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $5.38
Upside: +48.84%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $252.27
Upside: -0.90%
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $18.79
Upside: -14.85%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $6.30
Upside: +11.11%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $13.63
Upside: +24.72%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $126.19
Upside: -6.49%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $140.18
Upside: +11.29%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $90.24
Upside: +16.36%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $86.09
Upside: -53.54%